Interventions for treatment of herpes simplex labialis (cold sores on the lips)

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Chuanfang Lee ◽  
Ching-Chi Chi ◽  
Shu-Ching Hsieh ◽  
Charn-Jung Chang ◽  
Finola M Delamere ◽  
...  
Keyword(s):  
Herpes Simplex ◽  
Cold Sores

scholarly journals Protocol for a randomised controlled trial of 90% kanuka honey versus 5% aciclovir for the treatment of herpes simplex labialis in the community setting

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e017766 ◽  
Author(s):  
Alex Semprini ◽  
Joseph Singer ◽  
Nicholas Shortt ◽  
Irene Braithwaite ◽  
Richard Beasley
Keyword(s):  
New Zealand ◽  
Herpes Simplex ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Healing Time ◽  
Research Network ◽  
Cold Sore ◽  
Cold Sores ◽  
Randomised Controlled ◽  
Medical Grade

IntroductionWorldwide, about 90% of people are infected with the herpes simplex virus, 30% of whom will experience recurrent herpes simplex labialis, commonly referred to as ‘cold sores’, which can last up to 10 days. The most common treatment is aciclovir cream which reduces healing time by just half a day compared with no specific treatment. This is a protocol for a randomised controlled trial (RCT) to determine the efficacy of medical grade kanuka honey-based topical treatment (Honevo) in reducing the healing time and pain of cold sores, compared with topical aciclovir treatment (Viraban).Methods and analysisThis open-label, parallel-group, active comparator superiority RCT will compare the efficacy of medical grade kanuka honey with 5% aciclovir cream in the treatment of cold sores in the setting of a pharmacy research network of 60 sites throughout New Zealand. Adults presenting with a cold sore (N=950) will be randomised by pharmacy-based investigators. The pharmacy-based investigators will dispense the investigational product to randomised participants and both study groups apply the treatment five times daily until their skin returns to normal or for 14 days, whichever occurs first. In response to a daily SMS message, participants complete an assessment of their cold sore healing, with reference to a visual guide, and transmit it to the investigators by a smartphone eDiary in real time. The primary outcome variable is time (in days) from randomisation to return to normal skin. Secondary endpoints include total healing time stratified by stage of the lesion at onset of treatment, highest pain severity and time to pain resolution.Ethics and disseminationNew Zealand Ethics Registration 15/NTB/93. Results will be published in a peer-reviewed medical journal, presented at academic meetings and reported to participants.Trial registration numberAustralia New Zealand Clinical Trials Registry: ACTRN12615000648527, pre-results.SCOTT Registration: 15/SCOTT/14Protocol version4.0 (12 June 2017)

scholarly journals Vaccine Development for Herpes Simplex Viruses: A Commentary of Special Issue Editors

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 158
Author(s):  
Antonella Caputo ◽  
Peggy Marconi
Keyword(s):  
Herpes Simplex ◽  
Vaccine Development ◽  
Human Pathogens ◽  
Herpes Simplex Viruses ◽  
Sexually Transmitted ◽  
Increased Risk ◽  
Cold Sores ◽  
Simplex Virus ◽  
Overt Disease

Herpes simplex virus type 1 and 2 (HSV1 and HSV2) are global, widespread human pathogens transmitted by direct contact that cause lifelong, recurrent asymptomatic and painful symptomatic clinical illnesses (cold sores, keratitis, blepharitis, meningitis, encephalitis, genital infections), overt disease and severe sequelae in neonatal and immune-compromised patients, and increased risk of cervical cancer and other sexually transmitted infections, including HIV [...]

scholarly journals Mucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections

2012 ◽  
Vol 2012 ◽  
pp. 1-22 ◽  
Author(s):  
Aziz Alami Chentoufi ◽  
Lbachir BenMohamed
Keyword(s):  
Herpes Simplex ◽  
Virus Infections ◽  
Viral Pathogens ◽  
Herpes Simplex Viruses ◽  
Cold Sores ◽  
Simplex Virus ◽  
Disseminated Disease ◽  
Hsv 1

Herpes simplex viruses type 1 and type 2 (HSV-1 and HSV-2) are amongst the most common human infectious viral pathogens capable of causing serious clinical diseases at every stage of life, from fatal disseminated disease in newborns to cold sores genital ulcerations and blinding eye disease. Primary mucocutaneous infection with HSV-1 & HSV-2 is followed by a lifelong viral latency in the sensory ganglia. In the majority of cases, herpes infections are clinically asymptomatic. However, in symptomatic individuals, the latent HSV can spontaneously and frequently reactivate, reinfecting the muco-cutaneous surfaces and causing painful recurrent diseases. The innate and adaptive mucosal immunities to herpes infections and disease remain to be fully characterized. The understanding of innate and adaptive immune mechanisms operating at muco-cutaneous surfaces is fundamental to the design of next-generation herpes vaccines. In this paper, the phenotypic and functional properties of innate and adaptive mucosal immune cells, their role in antiherpes immunity, and immunopathology are reviewed. The progress and limitations in developing a safe and efficient mucosal herpes vaccine are discussed.

scholarly journals Interventions for prevention of herpes simplex labialis (cold sores on the lips)

2015 ◽  
Author(s):  
Ching-Chi Chi ◽  
Shu-Hui Wang ◽  
Finola M Delamere ◽  
Fenella Wojnarowska ◽  
Mathilde C Peters ◽  
...  
Keyword(s):  
Herpes Simplex ◽  
Cold Sores
Sign in / Sign up

Export Citation Format

Share Document